NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70518-2138-00 | 70518-2138 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 12, 2019 | In Use | |
63629-3742-06 | 63629-3742 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 7, 2008 | In Use | |
70710-1744-03 | 70710-1744 | Dasatinib | Dasatinib | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
00085-1519-02 | 00085-1519 | Temozolomide | Temodar | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | Oct 22, 2014 | In Use |
71288-0161-20 | 71288-0161 | Leucovorin calcium | Leucovorin calcium | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Jul 19, 2023 | In Use | |
00078-0240-61 | 00078-0240 | Cyclosporine | Sandimmune | 25.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Mar 22, 2010 | In Use | |
61919-0218-10 | 61919-0218 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 1, 2014 | In Use | |
51672-1338-06 | 51672-1338 | Prednisolone Acetate | Flo-Pred | 16.7 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 17, 2008 | Mar 17, 2023 | In Use |
68788-8455-09 | 68788-8455 | hydrocortisone | HYDROCORTISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 5, 2023 | In Use | |
68788-8765-01 | 68788-8765 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov 12, 2024 | In Use | |
68382-0919-77 | 68382-0919 | methylprednisolone | methylprednisolone | 32.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
68071-1904-03 | 68071-1904 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 22, 2017 | In Use | |
83634-0454-61 | 83634-0454 | Leuprolide acetate | Leuprolide Acetate | 5.0 mg/mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Mar 15, 2025 | In Use | ||
73491-0627-01 | 73491-0627 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
83831-0121-04 | 83831-0121 | Cyclophosphamide | Frindovyx | 2.0 g/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Mar 19, 2025 | In Use | |
10019-0937-01 | 10019-0937 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | May 21, 2008 | In Use | |
61919-0365-21 | 61919-0365 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 1, 2014 | In Use | |
64842-0120-05 | 64842-0120 | FUTIBATINIB | LYTGOBI | 4.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Oral | Feb 3, 2023 | In Use | |
43063-0703-21 | 43063-0703 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 17, 2016 | In Use | |
00015-3211-30 | 00015-3211 | Carboplatin | Paraplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 1, 2007 | Jun 30, 2008 | In Use | |
43602-0176-01 | 43602-0176 | Bexarotene | Bexarotene | 75.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Sep 6, 2024 | In Use | |
63187-0526-10 | 63187-0526 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 3, 2015 | In Use | |
71335-9715-04 | 71335-9715 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 5, 2024 | In Use | |
13668-0593-86 | 13668-0593 | APREPITANT | APREPITANT | 125.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Oct 21, 2020 | In Use | |
59923-0726-30 | 59923-0726 | Erlotinib | Erlotinib | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | May 1, 2020 | In Use |
Found 11748 results — Export these results